Ricovr offers XALIVA® THC, a portable point‑of‑care saliva testing platform that detects recent cannabis use within a 10‑hour window. The system combines a disposable swab kit with an optical microfluidic cartridge to deliver results in about 15 minutes, providing high‑accuracy, lab‑grade detection without the need for laboratory processing. It enables HR staff, safety managers, and third‑party administrators in safety‑sensitive industries to conduct on‑site screening quickly and cost‑effectively, supporting compliance, safety, and productivity.
Funding
$75K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Employers in safety‑sensitive industries need a fast, reliable way to determine whether employees have used cannabis during work hours, but traditional urine or hair tests either detect use too far in the past or require costly lab processing.
Solution
Ricovr’s XALIVA® THC platform provides a point‑of‑care saliva‑based test that detects recent cannabis consumption within a 10‑hour window, matching the typical impairment period. The system combines a disposable swab kit with an optical microfluidic cartridge that delivers results in about 15 minutes without the need for a laboratory. The test uses a 10 ng/mL THC cut‑off, validated against mass‑spectrometry with 100 % concordance, ensuring high sensitivity and specificity. Its portable design enables on‑site screening by HR staff, supervisors, or third‑party administrators across construction, manufacturing, logistics, oil & gas, and other high‑risk sectors. By delivering rapid, accurate results, XALIVA® helps companies maintain safety, productivity, and regulatory compliance while reducing testing costs and turnaround time.
Target Audience
Primary customers are HR professionals, safety managers, and supervisors in safety‑sensitive industries (e.g., construction, manufacturing, logistics, oil & gas) as well as third‑party administrators who conduct on‑site drug screening.
Features
- Optical biosensor with microfluidic cartridge that processes a small saliva sample in ~15 minutes
- Immunoassay detection of THC at a 10 ng/mL cut‑off, validated 100 % against gold‑standard mass spectrometry
- Portable, battery‑operated device and disposable test kit for on‑site, point‑of‑care use
- Direct observation swab with built‑in indicator to ensure proper collection and privacy
- Results displayed instantly on the device and can be recorded for compliance reporting
- Supports multiple testing scenarios: random, reasonable suspicion, post‑accident, periodic, return‑to‑duty, and follow‑up